undamentalytics Newsletter
Sign in

Marker Therapeutics, Inc. revenue

Marker Therapeutics, Inc.'s revenue was $3.5m in fiscal 2025, down 46.2% on the year before. Since fiscal 2017 ($183,064) it has grown at a compound 44.8% a year. Over the last twelve months it was $3.9m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Revenue1832062135001,2423,5143,3116,5913,5473,949
Growth on the year before—+12.5%+3.5%+134.5%+148.3%+183.0%−5.8%+99.1%−46.2%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Grant $3.5M 100.0% ▼ 46.2%
Cancer Prevention and Research Institute of Texas Acute Myeloid Leukemia $900,014 25.4% ▼ 79.6%
National Institutes of Health Small Business Innovation Research For Lymphoma Grant $665,000 18.7% 0.0%
Cprit Pancreatic Grant $573,994 16.2% —
National Institutes of Health Small Business Innovation Research $472,208 13.3% ▼ 51.9%
National Institutes of Health Small Business Innovation Research For Pancreatic Cancer $425,670 12.0% ▲ 5831.0%
National Institutes of Health National Cancer Institute Grant $391,305 11.0% ▲ 6621.1%
Fda Grant $118,478 3.3% ▼ 77.2%

From Marker Therapeutics, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Marker Therapeutics, Inc. $3.9m -30.7% 1.4%
DBV Technologies S.a. $3.8m -31.6% -11.6%
Dyadic International Inc $3.8m -8.0% 3.4%
Aligos Therapeutics, Inc. $3.7m 19.4% -5.5%
Camp4 Therapeutics Corp $4.2m 40.2% —
Curis Inc $4.3m -62.2% -25.0%

Compare with peers

Head to head: DBVT vs MRKRDYAI vs MRKRALGS vs MRKR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Marker Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Marker Therapeutics, Inc.